DDIT3 and diffuse large B-cell lymphoma: This is an exciting time in the field of DLBCL; while the optimum sequence for CD19-targeting therapies following R-CHOP has yet to be determined, the last 5 years have at least provided several new avenues to explore, including further potential opportunities to improve on R-CHOP as first-line therapy.